Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

DPP-4 inhibitors and atherosclerosis: the promise.

Jialal I, Bajaj M.

Atherosclerosis. 2013 Apr;227(2):224-5. doi: 10.1016/j.atherosclerosis.2012.12.033. No abstract available.

PMID:
23395524
2.

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G.

Atherosclerosis. 2013 Apr;227(2):349-54. doi: 10.1016/j.atherosclerosis.2012.12.018.

PMID:
23375680
3.

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial..

Diabetes Care. 2016 Jan;39(1):139-48. doi: 10.2337/dc15-0781.

PMID:
26628419
4.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
5.

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.

Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Erratum in: Eur J Pharmacol. 2011 Mar 25;655(1-3):121. multiple author names added.

PMID:
20540938
6.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

7.

The role of dipeptidyl peptidase-4 inhibitors.

Lasserson D, Mant J.

BMJ. 2012 Mar 12;344:e1213. doi: 10.1136/bmj.e1213. No abstract available.

PMID:
22411917
8.
9.

Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?

Juillerat-Jeanneret L.

J Med Chem. 2014 Mar 27;57(6):2197-212. doi: 10.1021/jm400658e. Review.

PMID:
24099035
10.
11.

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

Thornberry NA, Gallwitz B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86. doi: 10.1016/j.beem.2009.03.004.

PMID:
19748065
12.

The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.

Green JB.

Postgrad Med. 2012 Jul;124(4):54-61. doi: 10.3810/pgm.2012.07.2566. Review.

PMID:
22913894
13.

Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.

Zhao Y, Yang L, Zhou Z.

J Diabetes. 2014 Jan;6(1):21-9. doi: 10.1111/1753-0407.12063. Review.

PMID:
23683065
14.

[Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].

Goda M, Akahoshi F, Ishii S, Terata R, Hayashi Y.

Nihon Yakurigaku Zasshi. 2013 Sep;142(3):134-43. Review. Japanese. No abstract available.

PMID:
24025495
15.

Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.

Urquhart BS.

Adv NPs PAs. 2010 Oct;1(2):38-44. Review. No abstract available.

PMID:
21299149
16.

Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.

Gustavson SM, Dai H, Preston GM, Somayaji V, Hirshberg B, Calle RA.

Diabetes Res Clin Pract. 2011 Feb;91(2):e45-9. doi: 10.1016/j.diabres.2010.10.018.

PMID:
21130513
17.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Erol A.

Clin Ther. 2008 Apr;30(4):785-6; author reply 786. No abstract available.

PMID:
18498926
18.

Report was overpositive about their benefits.

Scheffel RS, Schaan BD.

BMJ. 2012 Apr 24;344:e2917; author reply e2922. doi: 10.1136/bmj.e2917. No abstract available.

PMID:
22531806
19.

Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.

Power O, Nongonierma AB, Jakeman P, FitzGerald RJ.

Proc Nutr Soc. 2014 Feb;73(1):34-46. doi: 10.1017/S0029665113003601. Review.

PMID:
24131508
20.

[Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra].

Müller UA.

Dtsch Med Wochenschr. 2011 Mar;136(11):547. doi: 10.1055/s-0031-1272566. German. No abstract available.

PMID:
21351042
Items per page

Supplemental Content

Support Center